Why did Rapport Therapeutics, Inc's stock price soar before the market?
Source: CoinWorld
Time: 2025-09-08 22:32:33
Rapport Therapeutics (NASDAQ: RAPP) announced a positive phase 2a clinical trial of its epilepsy drug RAP-219, with shares soaring 143.66% to $34.99 in pre-market trading. The trial results showed a median seizure reduction of 77.8%, with 24% of patients completely ridding of seizures. The drug is well tolerated and no serious adverse events have been reported. The company plans to enter Phase 3 clinical trials in 2026.